Welcome to our dedicated page for B. Riley Financial news (Ticker: RILY), a resource for investors and traders seeking the latest updates and insights on B. Riley Financial stock.
B. Riley Financial, Inc. (NASDAQ: RILY) provides integrated financial solutions across investment banking, wealth management, and corporate advisory services. This dedicated news hub aggregates all essential updates about the company's operations, strategic initiatives, and market position.
Investors and analysts will find timely information on earnings announcements, mergers & acquisitions, leadership changes, and strategic partnerships. The curated collection includes press releases, regulatory filings, and third-party analysis to support informed decision-making.
Key coverage areas include capital market activities, restructuring developments, wealth management expansions, and financial consulting projects. Regular updates ensure stakeholders maintain current awareness of RILY's cross-platform initiatives in North American and European markets.
Bookmark this page for convenient access to verified RILY updates. Combine real-time alerts with historical context to track the company's evolving financial strategies and industry impact.
B. Riley Financial has announced cash dividends for its Preferred Stock series, specifically the 6.875% Series A and the 7.375% Series B. Each depositary share, representing 1/1000th of a share, has a liquidation preference of $25.00. The dividend for Series A is set at $0.42968750 per depositary share, while Series B is $0.4609375. These dividends are scheduled for payment on or around April 30, 2023, to holders of record as of April 21, 2023.
This announcement reaffirms B. Riley's commitment to providing returns to its shareholders, reflecting its financial stability and operational performance.
B. Riley Financial, Inc. (NASDAQ: RILY) announced it led financing for Harrow Health, Inc. (NASDAQ: HROW) to support its acquisition of exclusive commercial rights to five FDA-approved ophthalmic products. The financing included $59.75 million in debt provided in January 2023 and a fully backstopped $125 million commitment. The loan was fully repaid on March 27, 2023, coinciding with Harrow's new $100 million credit facility. B. Riley also managed Harrow's equity and senior notes offerings in December 2022, raising $65.25 million. Harrow aims to enhance its position in the U.S. ophthalmic pharmaceuticals market through this acquisition.
FAQ
What is the current stock price of B. Riley Financial (RILY)?
What is the market cap of B. Riley Financial (RILY)?
